In a recent study published in Nature Aging , researchers investigated whether sodium-glucose co-transporter 2 (SGLT2) inhibitors induce senolysis. Study: SGLT2 inhibition eliminates senescent cells and alleviates pathological aging . Image Credit: tomertu/Shutterstock.
com Senescent cells, responsible for aging, amass in tissues and endure permanent growth stops, leading to age-associated illnesses. However, blocking senescence regulators can induce cancer. Senolysis, or senescent cell removal, improves aging symptoms such as metabolic illness, cardiovascular disease, bone loss, and renal failure while prolonging life without raising cancer risk.
Caloric restriction can lengthen organisms' lifespans, and some research indicates that SGLT2 inhibitor drugs may have senolytic impacts. In the present study, researchers evaluated the senolytic effects of SGL2 inhibition. Researchers investigated the impact of SGLT2 inhibitors on the senescent cellular load in vivo.
They fed mice high-fat diets (HFD) for eight to ten weeks, followed by treatment with canagliflozin, an SGL2 inhibitor, for seven days. The team compared glucose metabolism following seven days of canagliflozin and insulin therapy to one week without canagliflozin administration. The researchers used transgenic mice to study the senolytic impact of canagliflozin.
They administered canagliflozin to mice for a week, with or without diphtheria toxins (DT). They evaluated the effect of restoring metabolic processes by HFD-f.
